415 related articles for article (PubMed ID: 18454306)
1. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
Stern DF
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
[TBL] [Abstract][Full Text] [Related]
2. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
3. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
4. Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
Lahlou H; Müller T; Sanguin-Gendreau V; Birchmeier C; Muller WJ
Cancer Res; 2012 Jun; 72(12):3080-90. PubMed ID: 22665265
[TBL] [Abstract][Full Text] [Related]
5. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
6. Targeting of erbB3 receptor to overcome resistance in cancer treatment.
Ma J; Lyu H; Huang J; Liu B
Mol Cancer; 2014 May; 13():105. PubMed ID: 24886126
[TBL] [Abstract][Full Text] [Related]
7. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
Smirnova T; Zhou ZN; Flinn RJ; Wyckoff J; Boimel PJ; Pozzuto M; Coniglio SJ; Backer JM; Bresnick AR; Condeelis JS; Hynes NE; Segall JE
Oncogene; 2012 Feb; 31(6):706-15. PubMed ID: 21725367
[TBL] [Abstract][Full Text] [Related]
8. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
9. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
Aurisicchio L; Marra E; Luberto L; Carlomosti F; De Vitis C; Noto A; Gunes Z; Roscilli G; Mesiti G; Mancini R; Alimandi M; Ciliberto G
J Cell Physiol; 2012 Oct; 227(10):3381-8. PubMed ID: 22213458
[TBL] [Abstract][Full Text] [Related]
10. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
[TBL] [Abstract][Full Text] [Related]
12. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
Holbro T; Beerli RR; Maurer F; Koziczak M; Barbas CF; Hynes NE
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8933-8. PubMed ID: 12853564
[TBL] [Abstract][Full Text] [Related]
13. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
Vijapurkar U; Kim MS; Koland JG
Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161
[TBL] [Abstract][Full Text] [Related]
14. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
15. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
Wang S; Huang J; Lyu H; Lee CK; Tan J; Wang J; Liu B
Cell Death Dis; 2013 Mar; 4(3):e556. PubMed ID: 23519125
[TBL] [Abstract][Full Text] [Related]
16. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
17. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1.
Chen J; Ren Q; Cai Y; Lin T; Zuo W; Wang J; Lin R; Zhu L; Wang P; Dong H; Zhao H; Huang L; Fu Y; Yang S; Tan J; Lan X; Wang S
Biochem Biophys Res Commun; 2018 Jun; 501(1):212-219. PubMed ID: 29715459
[TBL] [Abstract][Full Text] [Related]
19. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
